Tiny Drug Carriers for Better Brain Tumor Treatment
This patent describes super-small nanoparticle drug conjugates designed to sneak past barriers and spread evenly inside tough-to-treat tumors, especially in the brain, for more effective cancer therapy.
Patent Number
US 20240408251
Status
Active
Filing Date
December 19, 2023
Grant Date
—
Expiration
December 19, 2043
Claims
23
Assignee
Cornell University
Inventors
Jedd D. Wolchok, Cameron Brennan, Michael Overholtzer, Ulrich Wiesner, Michelle S. Bradbury, Barney Yoo
Citations
0 forward · 0 backward
What it covers
This patent describes a method for treating cancer using special tiny drug carriers called nanoparticle drug conjugates (NDCs). Each NDC has a nanoparticle, which is super small—no bigger than 20 nanometers in average diameter, and ideally between 3 to 8 nanometers (Claim 1, Claim 5). Attached to this nanoparticle is a 'linker-drug construct' where a drug is connected by a 'cleavable linker' (Claim 1). This linker can break apart, releasing the drug once it reaches the tumor (Claim 6). The key is that these NDCs are designed to easily spread and move around within the tumor tissue, called the 'tumor interstitium' (Claim 1). For example, these NDCs could carry a chemotherapy drug like gefitinib (Claim 9) directly into a glioblastoma multiforme (GBM) brain tumor (Claim 2), allowing the drug to reach more cancer cells effectively.
What it doesn't cover
- —Does not cover nanoparticle drug conjugates where the nanoparticle has an average diameter greater than 20 nanometers (Claim 1).
- —Does not cover drug delivery systems where the drug is not attached to a nanoparticle via a cleavable linker (Claim 1).
- —Does not cover methods of treating cancer that do not involve administering a nanoparticle drug conjugate designed to diffuse within tumor interstitium (Claim 1).
- —Does not cover nanoparticles that are not specifically designed to carry a drug moiety (Claim 1).
- —Does not cover treatments for conditions other than cancer (Claim 1).
The clever bit
The truly clever part is the combination of extremely small nanoparticle size (under 20 nm, ideally 3-8 nm) with a cleavable drug linker, specifically designed to allow the entire drug-carrying nanoparticle to readily diffuse and spread widely within the dense, often difficult-to-penetrate tumor tissue (Claim 1, Claim 5). This ensures the drug reaches more cancer cells, rather than just the outer edges of the tumor.
Why it matters
Treating brain tumors is incredibly challenging because the brain has natural defenses, like the blood-brain barrier, that block most drugs. This patent addresses that problem by proposing extremely small nanoparticles that can potentially bypass these barriers and spread throughout the tumor more effectively (Claim 1). This improved distribution could mean that less drug is needed, and it reaches more cancer cells, leading to better outcomes for patients with aggressive cancers like glioblastoma (Claim 2). It also aims to treat 'leptomeningeal metastases,' which are cancers that spread to the fluid around the brain and spinal cord (Claim 4).
Real-world examples
- 1.Targeted chemotherapy for glioblastoma multiforme (GBM)
- 2.Drug delivery for metastatic brain tumors
- 3.Enhanced treatment for non-small cell lung carcinoma (NSCLC)
- 4.Theranostic agents combining diagnosis and therapy for brain cancer
- 5.Improved delivery of immunotherapies to tumor microenvironments
Generated by PatentBrief · Not legal advice · patentbrief.org
US 20240408251 · 2026